137 related articles for article (PubMed ID: 15894838)
1. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis.
Asai M; Monkawa T; Marumo T; Fukuda S; Tsuji M; Yoshino J; Kawachi H; Shimizu F; Hayashi M; Saruta T
Hypertens Res; 2004 Dec; 27(12):971-8. PubMed ID: 15894838
[TBL] [Abstract][Full Text] [Related]
2. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
[TBL] [Abstract][Full Text] [Related]
3. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
Kohzuki M; Kanazawa M; Liu PF; Kamimoto M; Yoshida K; Saito T; Yasujima M; Sato T; Abe K
J Hypertens; 1995 Dec; 13(12 Pt 2):1785-90. PubMed ID: 8903652
[TBL] [Abstract][Full Text] [Related]
4. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
Sato A; Suzuki Y; Saruta T
Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
[TBL] [Abstract][Full Text] [Related]
5. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
6. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis.
Zhang L; Hao JB; Ren LS; Ding JL; Hao LR
Lab Invest; 2014 Aug; 94(8):839-50. PubMed ID: 24862968
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.
Tylicki L; Renke M; Rutkowski P; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2008; 42(4):381-8. PubMed ID: 19230172
[TBL] [Abstract][Full Text] [Related]
8. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
[TBL] [Abstract][Full Text] [Related]
9. The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat.
Leader CJ; Wilkins GT; Walker RJ
PLoS One; 2021; 16(11):e0260554. PubMed ID: 34843581
[TBL] [Abstract][Full Text] [Related]
10. Candesartan prevents the progression of mesangioproliferative nephritis in rats.
Nakamura T; Obata J; Onizuka M; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
Kidney Int Suppl; 1997 Dec; 63():S226-8. PubMed ID: 9407466
[TBL] [Abstract][Full Text] [Related]
11. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
Bianchi S; Bigazzi R; Campese VM
Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
[TBL] [Abstract][Full Text] [Related]
13. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
14. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
Bianchi S; Bigazzi R; Campese VM
Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
[TBL] [Abstract][Full Text] [Related]
16. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney.
Tylicki L; Rutkowski P; Renke M; Rutkowski B
Kidney Int; 2007 Nov; 72(9):1164-5. PubMed ID: 17943159
[No Abstract] [Full Text] [Related]
17. Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats.
Matsumoto K; Morishita R; Moriguchi A; Tomita N; Yo Y; Nishii T; Nakamura T; Higaki J; Ogihara T
Hypertension; 1999 Aug; 34(2):279-84. PubMed ID: 10454454
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[TBL] [Abstract][Full Text] [Related]
19. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.
Lin SL; Chen YM; Chien CT; Chiang WC; Tsai CC; Tsai TJ
J Am Soc Nephrol; 2002 Dec; 13(12):2916-29. PubMed ID: 12444210
[TBL] [Abstract][Full Text] [Related]
20. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis.
Kramer AB; van der Meulen EF; Hamming I; van Goor H; Navis G
Kidney Int; 2007 Mar; 71(5):417-24. PubMed ID: 17213874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
